Final Crenessity
Pharmacy benefit prior authorization guidance for Crenessity (crinecerfont) as adjunctive treatment to glucocorticoid replacement in adults and pediatric patients ≥ 4 years with classic congenital adrenal hyperplasia (CAH). Defines initial and continuation criteria, required prescriber specialties, dosing form considerations, approval durations, and documentation rights.
Annual Review Date and Last Revised Date listed as 11/20/2025.
Coverage Summary
Scope: Pharmacy benefit prior authorization guidance for Crenessity (crinecerfont) as adjunctive treatment to glucocorticoid replacement in classic congenital adrenal hyperplasia (CAH) for adults and pediatric patients ≥ 4 years of age. Coverage stance: covered_with_criteria. Initial approvals are for 6 months; continuation/extended approvals are for 1 year.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.